

# Anakinra eye drops for the treatment of dry eye associated with graft-versus-host disease (GVHD): case report (Abstract Number: 3PC-021)

ML. MOYA MARTÍN , BM. RODRÍGUEZ SÁNCHEZ-LAULHÉ, A. MARTÍNEZ ESCUDERO, D. GUARINO PANTION, A. MONZON MORENO.

HOSPITAL UNIVERSITARIO VIRGEN MACARENA, PHARMACY, SEVILLE, SPAIN.


## Background and importance

Severe dry eye syndrome affects the ocular surface, causing discomfort and visual disturbances.


## Aim and objectives

To describe a clinical case of a patient with severe dry eye syndrome treated with 2.5% Anakinra eye drops as an off-label use for topical ophthalmic administration to manage ocular dryness associated with graft-versus-host disease (GVHD).


## Materials and methods:



62-year-old male



Keratopathy due to severe dry eye syndrome secondary GVHD.



Leukemia: received therapy with TASPE August 2021 → ↓ visual acuity.

## Results:




No reponse to standard treatments → Off-label treatment




Sterile conditions: laminar flow hood.

## 2,5% Anakinra eye drops


0,67 ml of Kineret® 100 mg



3,33 mL of Viscofresh®




4 mL



7 days at 2-8°C



## Conclusion and relevance:

1 1 drop every 8 hours → 2 1 drop every 12 hours →  Symptomatic improvement

This information suggests formulation could be a **promising alternative** for managing severe dry eye syndrome.

